×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Welcome, Opening Remarks, and Keynote Address – Future of Medicine: Combination Products
Session Chair(s)
James Wabby, MHS
Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, United States
Combination products are emerging as innovative medical products due to their contribution to advancing medical care and are thus expected to have major impact in the coming years. Future technologies are most appealing to patients with ongoing medical conditions that require consistent treatment with daily injections or weekly procedures and unmet medical needs. Overall, the successful development of combination products will require great collaboration within the industry to overcome regulatory, clinical, and technical challenges.
Learning Objective : At the conclusion of this session, participants should be able to:
- Analyze the latest Office of Combination Products (OCP) regulatory expectations and challenges
- Recognize potential future innovation platforms
- Identify potential and future Global Convergence/Harmonization initiatives for combination products
Speaker(s)
Future of Medicine: Combination Products
Thinh X. Nguyen
FDA, United States
Director, Office of Combination Products, OCPP
Have an account?